H.C. Wainwright Initiates Coverage on SINTX Technologies with Buy Rating, Highlighting Silicon Nitride Platform Opportunity
April 23, 2026
Independent analyst coverage underscores SINTX’s transition to a commercial-stage biomaterials company, citing its silicon nitride technology, recent FDA clearance and first human implant, and a scalable platform strategy across orthopedics and adjacent healthcare markets.
Recent News
- Freyya Closes Oversubscribed Pre-Seed Financing to Advance FDA Regulatory Milestones, Commercialization
- In Memory of Dr. Michael Rinck, Founder, MT Promedt Consulting GmbH
- bioMérieux Launches SPINCHIP® hs-cTnl, a Major Innovation for the Measurement of High-Sensitivity Cardiac Troponin I and Faster Management of Cardiac Emergencies
- Priority Review Granted for PolarityBio’s SkinTE for Treatment of Diabetic Foot Ulcers
- National Institutes of Health Award Inherent Biosciences a Direct-to-Phase II SBIR Grant
- Co-Diagnostics to Participate in Global Health Roundtable on Ebola and Outbreak Innovation
